Clinical Trials

134 enrolled

Carcinoma, Renal Cell

NCT04071236 2026-03-18

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

90 enrolled

Phase 1 Active not recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

Phase 3 Completed

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT05133440 2026-01-21

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

12 enrolled

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

2 enrolled

Prostatic Neoplasms

NCT03737370 2025-10-07

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

43 enrolled

Prostatic Neoplasms

NCT04521361 2025-09-19

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

46 enrolled

Bone Metastatic Castration-resistant Prostate Cancer

NCT03361735 2025-05-02

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled

Prostate Adenocarcinoma

NCT03304418 2025-04-30

RROPE

20 enrolled 14 charts

Prostate Cancer Metastatic to Bone

NCT03076203 2025-04-29

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

14 enrolled

Prostate Carcinoma Metastatic to the Bone

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02043678 2025-02-19

ERA 223

Phase 3 Completed

806 enrolled 32 charts

Prostatic Neoplasms

NCT03002220 2024-12-11

EXCAAPE

52 enrolled 15 charts

Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

40 enrolled 18 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

122 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT05771896 2023-09-14

CARE

Phase 3 Withdrawn

Prostatic Neoplasms

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

100 enrolled

Hormone Refractory Prostate Cancer

NCT02346526 2022-09-29

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

22 enrolled 14 charts

Prostatic Neoplasms

NCT02582749 2022-07-11

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Phase 2 Terminated

16 enrolled 6 charts

Prostatic Neoplasms

NCT03062254 2021-09-21

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

14 enrolled

Prostatic Neoplasms

NCT03458559 2020-11-17

RaRe

Phase 3 Unknown

402 enrolled

Prostatic Neoplasms

NCT02199197 2020-10-30

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

49 enrolled 18 charts

Prostatic Neoplasms

NCT02406521 2020-03-04

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

30 enrolled

Carcinoma, Renal Cell

NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

45 enrolled

Castrate-Resistant Prostate Cancer

NCT02034552 2019-07-23

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

68 enrolled 17 charts

Prostatic Neoplasms

NCT02023697 2019-07-12

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

391 enrolled 53 charts

Prostatic Neoplasms

NCT02507570 2019-03-19

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

40 enrolled

Prostate Carcinoma Metastatic to the Bone

NCT01810770 2018-09-19

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Phase 3 Completed

243 enrolled

Prostatic Neoplasms

NCT01929655 2018-04-24

Japanese BAY88-8223 Monotherapy Phase II Study

49 enrolled

Prostatic Neoplasms

NCT01934790 2018-03-26

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Phase 1/2 Completed

45 enrolled 23 charts

Prostatic Neoplasms

NCT02097303 2018-02-01

eRADicAte

36 enrolled 13 charts

Prostatic Neoplasms

NCT01565746 2016-10-17

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

19 enrolled

Prostatic Neoplasms

NCT02656563 2016-10-14

RAND

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00667537 2015-12-14

PK in Pts With HRPC & Skeletal Metastes

6 enrolled

Prostatic Neoplasms

NCT02396368 2015-11-20

Radium-223

Phase 1 Withdrawn

Prostatic Neoplasms

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

64 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT00748046 2014-06-25

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

10 enrolled